Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has proved helpful vigilantly but unsuccessfully to create an one off therapy, variously named Pro 140, leronlimab, and Vyrologix.

In development of this particular treatment, CytoDyn has cast its net wide and far both geographically and in phrases of prospective indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will actually be being used is actually an open question.

While CYDY  is actually dawdling, promote opportunities for leronlimab as being a combination therapy in the curing of multi-drug-resistant HIV are actually closing.

I am writing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale of the past several shares of mine. The first CytoDyn article of mine, “CytoDyn: What To Do When It is Too Good to be able to Be True?”, set out what follows prediction:

Instead I expect it to become a serial disappointer. CEO Pourhassan presented such a very promotional picture in the Uptick Newswire employment interview that I came away with a poor viewpoint of the company.

Irony of irony, my bad viewpoint of the business has grown steadily, though the disappointment has not been financial. Two many years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > 6 bagger at the moment still disappoints? Therein sits the story; let me explain.

CytoDyn acquired its much-storied treatment (which I shall relate to as leronlimab) back throughout 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for the treatment as well as avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti viral activity of HIV- infected subjects. Today’s payment of $3.5 zillion transfers ownership of the expertise and also connected intellectual property coming from Progenics to CytoDyn, and approximately 25 million mg of bulk drug substance…. milestone payments after commencement of a phase III clinical trial ($1.5 million) plus the first brand new drug program approval ($5 million), as well as royalty payments of five % of net sales upon commercialization.

Since that point in time, CytoDyn’s helping nous, Nader Pourhassan [NP] has made this inauspicious acquisition into a springboard for CytoDyn to buy a sector cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with multiple therapies and numerous indications, it has this individual remedy and a “broad pipeline of indications” as it puts it. I call certain pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a potentially beneficial therapy in dozens of indications.

The opening banner of its on the website of its (below) shows an energetic business with diverse interests albeit centered on leronlimab, multiple disease types, multiple presentations in addition to multiple publications.

Can all this be smoke and mirrors? That’s a question I’ve been asking myself with the very start of my interest in this business. Judging by the multiples of thousands of diverse comments on listings accessible through Seeking Alpha’s CytoDyn Summary page, I’m far from alone in this question.

CytoDyn is a classic battleground, or even some could say cult inventory. Its adherents are fiercely protective of the prospects of its, quick to label any bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *